CYT107: Phase I/IIa started

Cytheris began a single-blind, placebo-controlled, dose-escalation, international Phase I/IIa trial in 50 patients with CD4 T lymphocyte counts between 101-400 cells/mm 3 and plasma HIV RNA < 50 copie...